Non-Viral Drug Delivery Systems Market CAGR To Exceed 9.0% by 2035, Due To The Growing Demand For Biologics | Roots Analysis

According to our latest market report "Non-Viral Drug Delivery Systems Market by Type of Molecule Delivered, Type of Biologic Delivered, Type of Vehicle Used, Target Therapeutic Area, Type of Payment Employed, Key Geographical Regions and Leading Players: Industry Trends and Global Forecasts, till 2035", the global non-viral drug delivery systems market size is projected to reach USD 20.4 billion by 2035 from USD 8.6 billion in the current year, growing at a CAGR of 9.0%. 

Non-viral drug delivery systems are at the forefront of innovative technologies for intracellular delivery of biologic drugs which is precise in terms of targeting specific cells. These systems include exosome-based vehicles, cell-penetrating peptides and lipid nanoparticles, that offer significant advantages over viral methods, such as reduced immunogenicity and cytotoxicity.

Interestingly, non-viral vectors can transport a diverse range of genetic materials without the size limitations associated with viral vectors which makes non-viral vectors more versatile and cost-effective. As research continues to evolve, non-viral drug delivery systems market is poised to revolutionize therapeutic interventions across a variety of diseases.

Non-Viral Drug Delivery Systems Market Companies Profiled

Examples of companies engaged in non-viral drug delivery systems market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Arcturus Therapeutics, Bio-Path Holdings, CureVac, Entos Pharmaceuticals, etherna, Matinas Biopharma, MDimune and PCI Biotech

Non-Viral Drug Delivery Systems Market Regional Outlook

Based on the geographical regions, the non-viral drug delivery systems market can be segmented into three major regions, including North America, Europe and Asia-Pacific. North America is anticipated to capture the majority share of the non-viral drug delivery systems market in the current year. Further, the non-viral drug delivery systems in Asia-Pacific is accounted to be the fastest-growing segment of the market. This is primarily due to the rising demand for biologics owing to the growing chronic diseases.

Non-Viral Drug Delivery Systems Market Segments

Based on the Type of Molecule Delivered, the market is segmented into biologics and small molecules.

§  The biologics segment is likely to capture the largest revenue share of 95% in the non-viral drug delivery systems market, in the current year.

§  The small molecules segment is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 14.2% during the forecast period.

Based on the Type of Biologic Delivered, the market is segmented into RNA, DNA, proteins / peptides and antibodies.

§  The RNA segment is likely to capture the largest revenue share of 65% in the non-viral drug delivery systems market, in the current year.

§  The antibodies segment is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 18.4% during the forecast period.

Based on the Type of Vehicle Used, the market is segmented into nanoparticles, extracellular vesicles, polymers, oligonucleotides and cell penetrating peptides.

§  The nanoparticles segment is likely to capture the largest revenue share of 55% in the non-viral drug delivery systems market, in the current year.

§  The nanoparticles segment is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 9.7% during the forecast period.

Based on the Target Therapeutic Area, the market is segmented into oncological disorders, infectious diseases, cardiovascular disorders, genetic disorders, hepatic disorders, metabolic disorders, neurological disorders, pulmonary disorders, rare disorders and other disorders.

§  The oncological disorders segment is likely to capture the largest revenue share of ~30% in the non-viral drug delivery systems market, in the current year.

§  The infectious segment is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 10.7% during the forecast period.

Based on the Type of Payment Employed, the market is segmented into upfront payments and milestone payments.

§  The upfront segment is likely to capture the largest revenue share of ~60% in the non-viral drug delivery systems market, in the current year.

§  The milestone segment is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 11.5% during the forecast period.

Key Report Takeaways

§  Several key companies (established as well as start-ups) in the non-viral drug delivery systems domain claim to offer drug delivery technologies for delivering various types of molecules, including biologics and small molecules

§  Around 40% of the companies engaged in developing non-viral drug delivery systems are small firms; of these, majority of the firms are based in North America

§  In pursuit of gaining a competitive edge, industry stakeholders are actively innovating and developing novel non-viral drug delivery systems that can be utilized for the treatment of various indications

§  More than 1,140 patents related to non-viral drug delivery systems have been filed / granted by the technology providers in order to protect the intellectual property generated within this field

§  The rising interest in this domain is reflected by the rise in partnership activity; in fact, close to 65% of the deals were inked in the last three years

§  Owing to the numerous advantages offered by non-viral vectors, the non-viral drug delivery systems market is anticipated to grow at an annualized rate of 9.0% in the coming decade

§  The market opportunity is anticipated to be well-distributed across different types of molecule delivered, type of biologics delivered, type of vehicle used, target therapeutic area and key geographies

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com